Matches in SemOpenAlex for { <https://semopenalex.org/work/W2470249916> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W2470249916 abstract "Abstract Chronic myeloid leukaemia (CML) is characterised by the BCR-ABL oncoprotein. The amino-acid sequences spanning the junctional region are completely leukaemia-specific. In vitro pulsing of antigen presenting cells elicits immune response to CML cells. Vaccination of CML patients with peptides from this junctional region could therefore elicit/augment immune responses to CML cells. In our Evaluation of Peptide Immunisation in CML (EPIC) study, the patient’s entry requirements were as follows: first chronic phase of CML, expression of e14a2 (b3a2) BCR-ABL transcript, and prior treatment with imatinib daily (at least 400mg) at a stable dose for at least 6 months. Each patient received intradermally a cocktail of 3 BCR-ABL peptides: a 9-mer spanning the e14a2 region, the same 9-mer linked to PADRE (a 15-mer non-natural peptide shown to activate CD4+ T cells), and a 13-mer consensus e14a2 junctional peptide linked to PADRE. Peptides were administered at either 100 (5 patients), 300 (5 patients), 600 (5 patients), or 1000μg (4 patients) with sargramostim on 6 occasions over 2 months. Immune responses to the vaccine were monitored by IFN-γ and IL-5 ELISPOT assays on peripheral blood mononuclear cells. Molecular responses were assessed by quantitative real-time PCR of BCR-ABL mRNA. At entry no patient showed a detectable immune response to PADRE, but all 19 patients had detectable CD4+ T cells responses within 3 months of commencing vaccination. This indicated that the vaccination protocol was capable of stimulating T cell responses in all 19 patients. Immune responses to the 9-mer BCR-ABL junctional peptide used in the vaccine were detected in 11/19 patients, and demonstrated to be CD8+ T cells by cytokine analysis in flow cytometry. BCR-ABL immune responses were also assessed against a longer 18-mer peptide spanning the whole e14a2 junctional region. CD4+ T cells specific for this 18-mer peptide were detected in 14/19 patients. Interestingly, immunophenotyping indicated that these BCR-ABL-specific T cells were of a memory phenotype (CD45RO+). Serial molecular responses were available for at least 12 months on all cases. Of the 6 patients not in major cytogenic response (MCR) at baseline, molecular improvement was only observed in one case. However 12/13 patients in at least MCR at baseline had at least a 1 log fall in BCR–ABL transcripts, though this occurred several months after completing vaccination. Moreover, vaccination improved the fall in BCR–ABL transcripts in patients who had received imatinib for more than 12 months. These data show that peptide immunisation in CML can elicit anti-BCR-ABL peptide responses in CD4+ and CD8+ T cells. It also demonstrates that BCR-ABL peptide vaccination may improve control of CML, especially in patients responding well to imatinib." @default.
- W2470249916 created "2016-07-22" @default.
- W2470249916 creator A5011733008 @default.
- W2470249916 creator A5063461337 @default.
- W2470249916 creator A5072404159 @default.
- W2470249916 creator A5075177907 @default.
- W2470249916 date "2006-11-01" @default.
- W2470249916 modified "2023-09-30" @default.
- W2470249916 title "Clinical BCR-ABL Peptide Vaccination in Chronic Myeloid Leukaemia: Results of the EPIC Study." @default.
- W2470249916 doi "https://doi.org/10.1182/blood.v108.11.2197.2197" @default.
- W2470249916 hasPublicationYear "2006" @default.
- W2470249916 type Work @default.
- W2470249916 sameAs 2470249916 @default.
- W2470249916 citedByCount "0" @default.
- W2470249916 crossrefType "journal-article" @default.
- W2470249916 hasAuthorship W2470249916A5011733008 @default.
- W2470249916 hasAuthorship W2470249916A5063461337 @default.
- W2470249916 hasAuthorship W2470249916A5072404159 @default.
- W2470249916 hasAuthorship W2470249916A5075177907 @default.
- W2470249916 hasConcept C125418893 @default.
- W2470249916 hasConcept C126322002 @default.
- W2470249916 hasConcept C147483822 @default.
- W2470249916 hasConcept C170493617 @default.
- W2470249916 hasConcept C195616568 @default.
- W2470249916 hasConcept C203014093 @default.
- W2470249916 hasConcept C22070199 @default.
- W2470249916 hasConcept C2776090121 @default.
- W2470249916 hasConcept C2776789287 @default.
- W2470249916 hasConcept C2779053233 @default.
- W2470249916 hasConcept C42362537 @default.
- W2470249916 hasConcept C43907098 @default.
- W2470249916 hasConcept C502942594 @default.
- W2470249916 hasConcept C71924100 @default.
- W2470249916 hasConcept C86803240 @default.
- W2470249916 hasConcept C8891405 @default.
- W2470249916 hasConceptScore W2470249916C125418893 @default.
- W2470249916 hasConceptScore W2470249916C126322002 @default.
- W2470249916 hasConceptScore W2470249916C147483822 @default.
- W2470249916 hasConceptScore W2470249916C170493617 @default.
- W2470249916 hasConceptScore W2470249916C195616568 @default.
- W2470249916 hasConceptScore W2470249916C203014093 @default.
- W2470249916 hasConceptScore W2470249916C22070199 @default.
- W2470249916 hasConceptScore W2470249916C2776090121 @default.
- W2470249916 hasConceptScore W2470249916C2776789287 @default.
- W2470249916 hasConceptScore W2470249916C2779053233 @default.
- W2470249916 hasConceptScore W2470249916C42362537 @default.
- W2470249916 hasConceptScore W2470249916C43907098 @default.
- W2470249916 hasConceptScore W2470249916C502942594 @default.
- W2470249916 hasConceptScore W2470249916C71924100 @default.
- W2470249916 hasConceptScore W2470249916C86803240 @default.
- W2470249916 hasConceptScore W2470249916C8891405 @default.
- W2470249916 hasLocation W24702499161 @default.
- W2470249916 hasOpenAccess W2470249916 @default.
- W2470249916 hasPrimaryLocation W24702499161 @default.
- W2470249916 hasRelatedWork W1970289093 @default.
- W2470249916 hasRelatedWork W2001055320 @default.
- W2470249916 hasRelatedWork W2010003444 @default.
- W2470249916 hasRelatedWork W2054529397 @default.
- W2470249916 hasRelatedWork W2166919567 @default.
- W2470249916 hasRelatedWork W2220102944 @default.
- W2470249916 hasRelatedWork W2369978350 @default.
- W2470249916 hasRelatedWork W2470249916 @default.
- W2470249916 hasRelatedWork W3208258566 @default.
- W2470249916 hasRelatedWork W4221063257 @default.
- W2470249916 isParatext "false" @default.
- W2470249916 isRetracted "false" @default.
- W2470249916 magId "2470249916" @default.
- W2470249916 workType "article" @default.